Peyronie's disease is characterized by the presence of a collagen plaque on the shaft of the penis, which can distort an erection and make sexual intercourse difficult or even impossible in advanced cases. In some mild cases, the plaque can resolve spontaneously without medical intervention. In severe cases, the penis can be bent at a 90-degree angle during erection.

XIAFLEX is the first and only FDA- and EMA-approved biologic therapy indicated for the treatment of Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy.

Peyronie's disease affects between 3-9% of the male population and it can cause significant psychological distress in patients who are sexually active. Frequent patient complaints include increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction. The cause of Peyronie's disease is unknown, although some investigators have proposed that it may be due to trauma or an autoimmune component. A number of researchers have suggested that the incidence of Peyronie's disease has increased due to the use of erectile dysfunction drugs.

Endo has launched several direct-to-consumer initiatives intended to increase patient awareness of XIAFLEX as a possible treatment option for Peyronie's disease.

For full prescribing information, please visit www.xiaflex.com.